1. Introduction
===============

Epilepsy is a neurological disorder characterized by recurrent unprovoked seizures.^\[[@R1],[@R2]\]^ Its clinical manifestation is uncontrolled electrical activity produced by a group of abnormal neurons.^\[[@R1]\]^ Carbamazepine (CBZ) is an older drug, but is still widely used as an antiepileptic drug for the treatment of seizures.^\[[@R3]\]^

Carbamazepine is almost completely metabolized in the liver, and only approximately 5% of the compound is excreted from the body in its original form.^\[[@R4]\]^ The metabolic processes for CBZ are complex, and over 30 metabolites have been identified in human and animal models.^\[[@R5]--[@R7]\]^ CBZ is mainly metabolized by CYP3A4, CYP3A5, and CYP2C8, with CYP3A4 and CYP3A5 predominating.^\[[@R8]\]^ CBZ is also partly metabolized to 2-hydroxy-CBZ and 3-hydroxy-CBZ by CYP3A4 and CYP2B6,^\[[@R9]\]^ and the pharmacologically active metabolite is CBZ-10, 11-epoxide.^\[[@R8]\]^ Because the CYP3A5 contribution to the total CYP3A content is relatively small, the role of CYP3A5 is often ignored^\[[@R10]\]^; however, recent studies have focused on its functionally and quantitatively vital role in the metabolism of CYP3A substrates.^\[[@R11],[@R12]\]^

Carbamazepine N-glucuronide and glucuronides of hydroxylated metabolites are produced via the urinary metabolic pathway; therefore, glucuronidation is also important in CBZ metabolism.^\[[@R13]\]^ One study found that glucuronide metabolites are generated from 13 hydroxylated metabolites of CBZ, suggesting an important role for glucuronide not only with regard to CBZ itself but also to its metabolites.^\[[@R6]\]^ Moreover, a sensitive liquid chromatography/mass spectrometry assay study found that CBZ is specifically glucuronidated by the human UGT2B7 enzyme.^\[[@R13]\]^

Genetic variants can influence the substrate specificity and specific activity of enzymes, binding efficiencies of transcription factors and membrane proteins, and other features and functions. Relevant *CYP3A5* gene polymorphisms have been found, and the most common of which is *CYP3A5∗3* (rs776746), leading to reduced activity of the CYP3A5 enzyme.^\[[@R11]\]^ Nonetheless, large amounts of CYP3A5 enzyme are expressed in individuals with at least 1 *CYP3A5∗1* allele.^\[[@R11],[@R14]\]^ Two nonsynonymous variants, *UGT2B7∗2* (802C\>T, rs7439366) and *UGT2B7∗3* (211G\>T, rs12233719), have been identified thus far.^\[[@R15],[@R16]\]^ It has been reported that *UGT2B7∗2* decreases,^\[[@R15],[@R17]\]^ increases,^\[[@R18],[@R19]\]^ or does not affect^\[[@R20],[@R21]\]^ activity of the UGT2B7 enzyme. Similarly, *UGT2B7∗3* was found to reduce carvedilol glucuronidation activity^\[[@R22]\]^ or was conversely associated with higher enzyme activity.^\[[@R23]\]^ Although more than 30 single-nucleotide polymorphisms (SNPs) of *CYP3A4* have been identified, due to the very low frequencies of different *CYP3A4* alleles,^\[[@R24]\]^ polymorphisms in this gene were not examined in our study. Instead, *CYP3A5∗3, UGT2B7∗2*, and *UGT2B7∗3*---significant variants that can influence enzyme activity---were selected for investigation in our study and were confirmed by in vivo and in vitro analyses.^\[[@R5]--[@R7]\]^

Here, we investigate whether *CYP3A5∗3* and *UGT2B7∗2, UGT2B7∗3* can influence steady-state CBZ concentrations in Chinese epileptic patients. This study is the first to examine the effects of *CYP3A5∗3* and *UGT2B7∗2, UGT2B7∗3* alone, and *UGT2B7∗2, UGT2B7∗3* haplotypes on steady-state CBZ concentrations in these patients.

2. Methods
==========

2.1. Patients and study design
------------------------------

Patients were enrolled from Xiangya Hospital and The Second Xiangya Hospital. The ethics committee of Xiangya Medical School of Central South University approved the study. Patients over 18 years old and the parents of patients under 18 provided written informed consent, in compliance with the code of ethics of the World Medical Association (Declaration of Helsinki). The Chinese Clinical Trail Register approved the study (registration number: ChiCTR-RO-12002853). Patients were eligible for enrollment if they were treated with CBZ monotherapy and the course of treatment was more than 3 months; CBZ concentration data from therapeutic drug monitoring were available; and clinical data such as seizure types, medication history, CBZ doses, and time were available. Exclusion criteria were as follows: using drugs that could influence metabolic P450 enzymes and the UGT2B7 enzyme; having a history of alcohol and drug abuse and suffering serious side effects of drugs, resulting in poor compliance; and having progressive and degenerative neurological diseases or systemic diseases, including liver and kidney dysfunction. Standardized questionnaires were used to collect clinical and demographic data.

2.2. Blood sampling and drug assays
-----------------------------------

To ensure the collection of steady-state CBZ plasma concentrations, no dose adjustments were made within 1 month before the collection, and plasma samples were drawn early in the morning before the administration of the morning dose. Blood samples for genotyping were collected by venipuncture. High-performance liquid chromatography--UV (SHIMADZU Inc., Japan) in the therapeutic drug monitoring department of Xiangya Hospital was used to detect CBZ concentrations according to the methods of a previous publication.^\[[@R25]\]^

2.3. Genotypic analysis
-----------------------

DNA was extracted using the phenol-chloroform method. PCR-based direct sequencing was used to assess *CYP3A5∗3*, *UGT2B7∗2*, and *UGT2B7∗3* variants. *CYP3A5∗1* and *CYP3A5∗3* were defined as c.219--237 A allele and c.219--237 G allele, respectively. *UGT2B7∗1* (268H) and *UGT2B7∗2* were defined as c.802 C allele and c.802 T allele, respectively. *UGT2B7∗1* (71A) and *UGT2B7∗3* were defined as c.211 G allele and c.211 T allele, respectively. *UGT2B7∗1/∗1* (268H) and *UGT2B7∗1/∗1* (71A) were defined as c.802 CC genotype and c.211 GG genotype, respectively. The primers designed and annealing temperatures for PCR are provided in Table [1](#T1){ref-type="table"}. The PCR reaction contained 2 μL 10× PCR Buffer (Takara, Dalian, China), 1 μL 2.5 mM dNTPs (Takara, Dalian, China), 0.4 μL each 10 μM forward and reverse primers (Boshang Company, Beijing, China), 0.2 μL 5 u/μL rTaq enzyme (Takara, Dalian, China), 1 μL gDNA, and ddH~2~O to 20 μL. The amplification conditions were as follows: initial denaturation for 5 minutes at 98°C, followed by 36 cycles of 98°C for 30 seconds, the annealing temperature (specific temperature shown in Table [1](#T1){ref-type="table"}) for 30 seconds, and 72°C for 30 seconds, and a 5-minute extension at 72°C. The PCR products were detected using an ABI 3730xl (Applied Biosystems, California, USA).

###### 

PCR-based Sanger sequencing for *CYP3A5* and *UGT2B7* polymorphisms.
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2.4. Statistical analysis
-------------------------

All statistical analyses were carried out using SPSS software (version 11.0 for Windows; SPSS, Chicago, IL). Measurement data following a normal distribution were expressed as the mean ± standard deviation (*x* ± *s*). The unpaired *t* test or Wilcoxon rank-sum test was used for comparing clinical and demographic data. Hardy--Weinberg equilibrium was analyzed with the chi-square test. The dose-normalized CBZ concentration was calculated using the CBZ concentration (μg/mL) against the CBZ dose (mg). Body weight-normalized doses were calculated using the CBZ dose (mg) against body weight (kg). Stepwise multiple linear regression analysis was applied to evaluate relationships between multiple factors (CBZ doses, *CYP3A5∗3*, *UGT2B7∗2*, and *UGT2B7∗3* variants, body weight, and body mass index \[BMI\])) and dose-normalized CBZ concentrations. Haplotypes and their frequencies were estimated using haploview software (<http://www.broad.mit.edu/personal/jcbarret/haplo/>). A *P* value \<.05 was considered statistically significant.

3. Results
==========

3.1. Demographic characteristics of patients and genotyping results
-------------------------------------------------------------------

In all, 78 patients were eligible for the study; 16 patients were excluded for not meeting the inclusion criteria (n = 5), declining to participate (n = 3), or for other reasons related to the exclusion criteria (n = 8) (Fig. [1](#F1){ref-type="fig"}). The *CYP3A5* and *UGT2B7* genotypes of all patients are shown in Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}. Of the 62 patients enrolled, 32 were males and 30 were females. All enrolled patients in our study were local Han Chinese. The average age was 24.0 ± 16.2 years. The average daily carbamazepine dose was 499 ± 278 mg. The average concentration of CBZ was 4.17 ± 2.33 μg/mL. There were no differences between CYP3A5 expressors and nonexpressors regarding age, sex, body weight, or BMI (Table [2](#T2){ref-type="table"}). Moreover, there were no differences among *UGT2B7* genotypic groups regarding age, sex, body weight, or BMI (Table [3](#T3){ref-type="table"}). The distributions of *CYP3A5*∗3, *UGT2B7*∗2, and *UGT2B7*∗3 are shown in Table [4](#T4){ref-type="table"}. All allele frequencies were consistent with Hardy--Weinberg equilibrium.

![Flow diagram of enrolled patients.](medi-97-e11662-g002){#F1}

###### 

Demographic characteristics of all patients and *CYP3A5* genotypic groups.

![](medi-97-e11662-g003)

###### 

Demographic characteristics of *UGT2B7* genotypic groups.
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###### 

Distributions of *CYP3A5* and *UGT2B7* variants among all patients.
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3.2. Correlations between dose and serum concentration of CBZ
-------------------------------------------------------------

Positive correlations between CBZ dose and serum concentration were observed in all patients (*r* = 0.5819, *P* \< .0001), and CYP3A5 expressors (*r* = 0.4159, *P* = .0249) and nonexpressors (*r* = 0.6252, *P* = .0001), and *UGT2B7* genotypic groups (∗1/∗1(268H): *r* = 0.415, *P* = .0226; ∗1/∗2+∗2/∗2: *r* = 0.6245, *P* = .0001; ∗1/∗1(71A): *r* = 0.5223, *P* = .0005; ∗1/∗3+∗3/∗3: *r* = 0.6993, *P* = .0003, separately). After CBZ concentrations were normalized according to dose administered, negative correlations between doses and dose-normalized CBZ concentrations were observed in all patients (*r* = −0.3239, *P* = .0102), including CYP3A5 expressors (*r* = −0.395, *P* = .034) and nonexpressors (*r* = −0.625, *P* = .023), and *UGT2B7* genotypic groups (∗1/∗1(268H): *r* = −0.6321, *P* = .0002; ∗1/∗1(71A); ∗1/∗3+∗3/∗3: *r* = −0.4740, *P* = .002, separately). The value of the dose increased and the dose-normalized CBZ concentration decreased in all patients and in CYP3A5 expressors, and also *UGT2B7∗*1, *UGT2B7*∗2, *UGT2B7*∗3 patients (Fig. [2](#F2){ref-type="fig"}). However, there was no correlation between dose and dose-normalized CBZ concentration in *UGT2B7*∗1/∗2+∗2/∗2 patients (*r* = −0.2895, *P* = .1080).

![Correlations between doses and serum concentration of CBZ. The figures above present correlations between the dose and serum concentration of CBZ in (Aa) all patients, (C) CYP3A5 expressors and nonexpressors, (E) *UGT2B7*∗1/∗1(268H) and ∗1/∗2+∗2/∗2 patients, (G) *UGT2B7*∗1/∗1(71A) and ∗1/∗3+∗3/∗3 patients. The following figures present correlations between the dose and dose-normalized CBZ concentration in (B) all patients, (D) CYP3A5 expressors and nonexpressors, (F) *UGT2B7*∗1/∗1(268H) and ∗1/∗2+∗2/∗2 patients, (H) *UGT2B7*∗1/∗1(71A) and ∗1/∗3+∗3/∗3 patients. Open circle, CYP3A5 nonexpressors and *UGT2B7* mutants; closed circle, CYP3A5 expressors and wild-type *UGT2B7*. Solid line, regression line for CYP3A5 expressors and wild-type *UGT2B7*; dotted line, regression line for CYP3A5 non-expressors and mutant *UGT2B7*. CBZ = carbamazepine.](medi-97-e11662-g006){#F2}

3.3. Multiple linear regression analysis of serum CBZ concentration
-------------------------------------------------------------------

Multiple linear regression analysis was applied to evaluate relationships among CBZ dose, *CYP3A5∗3*, *UGT2B7∗2*, and *UGT2B7∗3* variants, body weight, BMI, and serum concentration of CBZ, and to compare the significance of each variable. With the equation, R2, β, ΔF, variance inflation factor, the *F* value, and the *P* value were obtained. According to the results, the CBZ dose was significantly correlated with the dose-normalized CBZ concentration (*β* = 0.682, *P* \< .001) (Table [5](#T5){ref-type="table"}). When *UGT2B7* ∗2 was added in step 2, a significant increase was observed in *R*^2^ (Δ*F* = 18.515, *P* \< .001). Therefore, the CBZ dose and *UGT2B7* ∗2 are correlated with the dose-normalized CBZ concentration.

###### 

Relationship between CBZ concentration and each independent variable using stepwise multiple linear regression.
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3.4. Comparison of CBZ serum levels and the required doss relative to the *CYP3A5* genotype
-------------------------------------------------------------------------------------------

After comparing the steady-state CBZ concentration, required dose, dose-normalized concentration, and body weight-normalized dose, we observed no significant difference between CYP3A5 expressors and nonexpressors (Fig. [3](#F3){ref-type="fig"}). Thus, the *CYP3A5∗3* genotype does not appear to affect the CBZ serum concentration or dose.

![Comparison of CBZ serum levels and required doses in relation to *CYP3A5* genotype. (A) Steady-state CBZ concentration; (B) dose-normalized CBZ concentration; (C) CBZ dose requirement; (D) body weight-normalized CBZ dose requirement. Open circle, CYP3A5 nonexpressors; closed circle, CYP3A5 expressors. CBZ = carbamazepine.](medi-97-e11662-g008){#F3}

3.5. Comparison of CBZ serum levels and required doses in relation to *UGT2B7∗2* and *UGT2B7∗3* genotypes
---------------------------------------------------------------------------------------------------------

Based on a comparison of *UGT2B7∗1/∗1* and *UGT2B7∗1/∗2+∗2/∗2* patients, no differences in steady-state CBZ concentrations and body weight-normalized doses were observed (*P* = .564, *P* = .0596, respectively). However, the required CBZ dose and dose-normalized concentration differed between *UGT2B7∗1/∗1* and *UGT2B7∗1/∗2+∗2/∗2* patients (*P* = .0139, *P* = .032, respectively) (Fig. [4](#F4){ref-type="fig"}). In addition, *UGT2B7∗2* patients showed a lower dose-normalized concentration and required more doses to maintain a steady-state concentration to control seizures.

![Comparison of CBZ serum levels and required doses in relation to *UGT2B7∗2* genotype. (S) Steady-state CBZ concentration; (B) dose-normalized CBZ concentration; (C) CBZ dose requirement; (D) body weight-normalized CBZ dose requirement. Open circle, *UGT2B7*∗1/∗2+∗2/∗2 patients; closed circle, *UGT2B7*∗1/∗1(268H) patients. CBZ = carbamazepine.](medi-97-e11662-g009){#F4}

In a comparison of *UGT2B7∗1/∗1* and *UGT2B7∗1/∗3+∗3/∗3* patients, we found no differences in steady-state CBZ concentrations, dose-normalized concentrations, required CBZ doses, or body weight-normalized doses (*P* = .0575, *P* = .184, *P* = .676, *P* = .643, respectively) (Fig. [5](#F5){ref-type="fig"}). Moreover, we observed that *UGT2B7∗3* did not affect the CBZ dose requirement or steady-state CBZ concentration.

![Comparison of CBZ serum levels and required doses in relation to *UGT2B7∗3* genotype. (A) Steady-state CBZ concentration; (B) dose-normalized CBZ concentration; (C) CBZ dose requirement; (D) body weight-normalized CBZ dose requirement. Open circle, *UGT2B7*∗1/∗3+∗3/∗3 patients; closed circle, *UGT2B7*∗1/∗1(71A) patients. CBZ = carbamazepine.](medi-97-e11662-g010){#F5}

3.6. Comparison of CBZ serum levels and required doses in relation to *UGT2B7∗2* and *UGT2B7∗3* haplotypes
----------------------------------------------------------------------------------------------------------

Significant differences in body weight-normalized CBZ dose between *UGT2B7* GC and TT haplotypes were revealed by analysis of the 4 haplotypes of *UGT2B7∗2* and *UGT2B7∗3* (*P* *=* .0154). For *UGT2B7* GC haplotype patients, a higher body weight-normalized CBZ dose was required for the patient to maintain the steady-state concentration necessary to control seizures. In contrast, we observed no differences in steady-state CBZ concentrations, dose-normalized concentrations, or required CBZ doses among the 4 *UGT2B7* haplotypes (Fig. [6](#F6){ref-type="fig"}).

![Comparison of CBZ serum levels and required doses in relation to *UGT2B7∗2* and *∗3* haplotypes. (A) Steady-state CBZ concentration; (B) dose-normalized CBZ concentration; (C) CBZ dose requirement; (D) body weight-normalized CBZ dose requirement. CBZ = carbamazepine.](medi-97-e11662-g011){#F6}

4. Discussion
=============

To investigate interindividual variability of CBZ, we carried out a pharmacogenetic study on the relationship between metabolic gene variants of *CYP3A5* and *UGT2B7* and CBZ steady-state concentrations, dose-normalized concentrations, required doses, and body weight-normalized doses. Our results showed the *UGT2B7∗2* variant to be significantly associated with dose-normalized CBZ plasma concentrations and required doses in Chinese patients with epilepsy. Conversely, the variants *CYP3A5∗3* and *UGT2B7∗2* were not found to be associated with CBZ serum concentrations or required doses.

A series of enzymes are involved in the metabolism of CBZ, including CYP3A4, CYP3A5, CYP2C8, UGT2B7, and EPHX1.^\[[@R8],[@R13],[@R26]\]^ Previous studies found that the *CYP3A5∗3* variant could influence amlodipine, tacrolimus, and cyclosporine metabolism,^\[[@R27]--[@R29]\]^ but that it had no influence on the pharmacokinetics of midazolam or clopidogrel.^\[[@R30],[@R31]\]^ CYP3A5 metabolizes CBZ to carbamazepine 10,11-epoxide, which is the main active metabolite of CBZ.^\[[@R8]\]^ Therefore, we hypothesized that *CYP3A5∗3* may influence the steady-state concentration of CBZ in epileptic patients. In our study, the frequency of the *CYP3A5∗3* allele was 71.8%, consistent with the frequency in Asians according to the National Center for Biotechnology Information (NCBI) database. In our study, we observed that *CYP3A5∗3* did not influence the steady-state CBZ concentration, dose-normalized concentration, required dose, or body weight-normalized dose. Although our results were consistent with the research by Puranik et al,^\[[@R32]\]^ they were inconsistent with other previous studies.^\[[@R28],[@R33]\]^ For example, Park et al^\[[@R34]\]^ found that *CYP3A5∗3* affected CBZ concentrations in Korean epileptic patients, and Wang et al^\[[@R33]\]^ found that rs776746 and rs15524 in the *CYP3A5* gene tended to affect CBZ metabolism. However, the latter study enrolled patients who received CBZ plus phenytoin or phenobarbital, which could affect the expression of the P450 enzyme system and could complicate the CBZ metabolism. Moreover, as an inducer of CYP3A4/5 enzymes, CBZ might affect their expression levels.^\[[@R35]\]^ Whether the effect of *CYP3A5* variants on CBZ concentrations has a significant impact on outcomes remains unclear. Further research involving large sample sizes and multiple centers is needed to confirm our negative results for *CYP3A5* variants.

The glucuronidation metabolic pathway of CBZ is an important factor in its pharmacokinetics. CBZ and its main active metabolite CBZ 10,11-epoxide are specifically glucuronidated by UGT2B7.^\[[@R13]\]^ Previous studies reported that the *UGT2B7∗2* variant, a missense mutation, can alter metabolic activity of modulating morphine,^\[[@R19]\]^ epirubicin,^\[[@R36]\]^ and efavirenz,^\[[@R37]\]^ but not valproic acid.^\[[@R38]\]^ In our study, the frequencies of the *UGT2B7∗*2 and *UGT2B7∗*3 alleles were 30.65% and 8.14%, respectively, which are similar to the frequencies in Asians according to the NCBI database. We found no differences in steady-state CBZ concentrations and body weight-normalized doses between *UGT2B7∗1/∗1* and *UGT2B7∗1/∗2+∗2/∗2* patients, though required CBZ doses and dose-normalized concentrations were different between these groups (*P* = .0139, *P* = .032, respectively) (Fig. [4](#F4){ref-type="fig"}). UG*T2B7∗1/∗2+∗2/∗2* patients exhibited a lower dose-normalized steady-state CBZ concentration as compared with *UGT2B7∗1/∗1* patients, but the former patients require a larger dose to achieve the steady-state CBZ concentration necessary to control seizures. Because different doses are used by epileptic patients to control seizures, we failed to show a correlation between the *UGT2B7∗2* genotype and steady-state CBZ concentration, which were not normalized by the CBZ dose. Multiple linear regression analysis also revealed that the CBZ dose and *UGT2B7*∗2 genotype are correlated with the dose-normalized CBZ concentration. Moreover, we observed significant relationships between the required CBZ dose and *UGT2B7∗2* genotype and a positive trend in the body weight-normalized CBZ required dose and *UGT2B7∗2* genotype (*P* = .0596). The *UGT2B7∗2* mutation replaced the histidine (His) at position 268 to a tyrosine (Tyr), resulting in an increase in enzyme activity. Thus, glucuronidation metabolism during CBZ excretion is increased, resulting in a lower dose-normalized steady-state CBZ concentration than in wild-type *UGT2B7* patients. Our results were consistent with a previous study reporting that *UGT2B7∗2* interactively affects the concentration--dose ratio of CBZ.^\[[@R39]\]^ Nonetheless, the relationship between *UGT2B7∗2* and CBZ concentration was negative in the study of Ma et al.^\[[@R40]\]^

We also investigated whether the *UGT2B7∗3* (Ala71Ser) variant affects steady-state CBZ concentrations. Although our results showed no significant impact for the *UGT2B7∗3* genotype on the CBZ concentration and required dose (Fig. [4](#F4){ref-type="fig"}), there was a trend toward a lower CBZ concentration and a lower dose-normalized concentration in *UGT2B7∗1/∗3+UGT2B7∗3/∗3* patients (*P* = .0575 and *P* = .184). Research on this variant is limited to date, though it has been demonstrated that *UGT2B7∗3* affects the pharmacokinetics of flurbiprofen,^\[[@R41]\]^ zidovudine,^\[[@R42]\]^ and carvedilol,^\[[@R43]\]^ but not R and S-carvedilol. We did not observe any significant effects of *UGT2B7∗3* on CBZ concentrations and dose requirements.

In our study, we carried out correlation analysis between dose and serum concentration of CBZ, and found positive correlations between all patients (*r* = 0.5819, *P* \< .0001) and *CYP3A5* or *UGT2B7* genotypic groups (all *P* \< .05). Although the correlations were significant, the *r* values were relative small. Therefore, we further carried out multiple linear regression analysis of serum CBZ concentration. According to the results, the CBZ dose was significantly correlated with the dose-normalized CBZ concentration *(β* = 0.682, *P* \< .001) (Table [5](#T5){ref-type="table"}). When *UGT2B7* ∗2 was added in step 2, a significant increase was observed in *R*^2^ (Δ*F* = 18.515, *P* \< .001). Therefore, the CBZ dose and *UGT2B7* ∗2 are correlated with the dose-normalized CBZ concentration.

There are some limitations to our study. First, despite efforts to enroll more patients, the enrolled sample size was small. Second, we explored the influence of *CYP3A5∗3, UGT2B7∗2*, and *UGT2B7∗3* variants on CBZ, but other gene variants may also affect CBZ concentrations. Because the samples size is small, we did not analyze the combination of 3 variants, which is also a limitation. Third, to correlate genetic polymorphisms with metabolism phenotypes, it is better to use the ratio of CBZ\'s major metabolites to CBZ. All of these aspects limited the results of our research. Larger samples and more genetic polymorphisms should be investigated in future work.

In summary, we explored the effects of *CYP3A5∗3, UGT2B7∗2*, and *UGT2B7∗3* variants on steady-state CBZ concentrations in 62 epileptic patients. Our study found that the *UGT2B7∗2* variant, but not the *CYP3A5∗3* and *UGT2B7∗3* variants, can affect steady-state CBZ concentrations in these patients.
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